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Abstract. This paper reviews some current methods for the in vivo assessment of local cutaneous
bioavailability in humans after topical drug application. After an introduction discussing the importance
of local drug bioavailability assessment and the limitations of model-based predictions, the focus turns to
the relevance of experimental studies. The available techniques are then reviewed in detail, with
particular emphasis on the tape stripping and microdialysis methodologies. Other less developed
techniques, including the skin biopsy, suction blister, follicle removal and confocal Raman spectroscopy
techniques are also described.
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INTRODUCTION
Skin is the largest organ of the human body and is
composed of three readily distinguishable layers: (a) the
stratum corneum (SC), which is the outermost part of the
epidermis, (b) the living epidermis, and (c) the dermis,
penetrated by a highly complex network of capillaries
involved in the removal of drugs from the skin into the
systemic circulation. In addition, several pilosebaceous and
sweat glands are dispersed throughout the skin, in various
numbers and size, depending on body site. The SC is well-
recognized as a heterogeneous two-compartment system of
ﬂattened keratinized cells embedded in a multilamellar lipid
matrix mainly composed of neutral lipids and ceramides
(1–4). It has a thickness of about 10 mm( 5–7)a n di s
composed of about 20 cell layers (5). Its main homeostatic
functions are restriction of excessive water loss to the
external environment, moisture retention, cell cohesion and
desquamation. In addition, SC is considered to be the rate-
controlling membrane for transport of xenobiotics across the
skin (although, for very lipophilic molecules, partitioning into
the more hydrophilic viable tissue may constitute the greater
resistance (2,8)). Therefore, topical skin bioavailability
assessment of xenobiotics is essential for both the (trans)-
dermal delivery of pharmacological active drugs and from a
toxicological point of view (9).
For systemically delivered oral products, bioavailability
is typically deﬁned as the rate and extent at which a drug
reaches the general circulation from an administered dosage
form. Dermatological drug products include a broad array
of preparations which are designed to exert a local effect
in diseased skin following topical application on the skin
surface. The objective is to maximize drug concentration
at the site of action within the skin with, ideally, a minimal
systemic uptake (10,11). Thus, systemic availability may not
properly reﬂect local cutaneous bioavailability (as it does
for transdermal products, on the other hand, which are
designed to deliver drug into the systemic circulation).
Moreover, topical doses tend to be so small (typically 2–5
mg of product/cm
2) that serum and/or urine concentrations
are often undetectable using conventional assay techniques
(12). A further complicating factor is the lack of knowledge
of the drug concentration needed at the skin target site
(with the exception of antifungal agents whose target site
is the SC surface). Topical bioavailability has been more
rigorously deﬁned as the temporal pattern of free drug
concentration at the target site [the so-called C* concept
(10)], but the value of this approach remains largely
theoretical due to the difﬁculty of quantifying drug within
the skin.
What options are available, then, for assessment of topical
bioavailability and bioequivalence? Although a drug_sp e r m e -
ability coefﬁcient through human skin can be estimated, for
example, from the molecular weight and octanol–water
partition coefﬁcient (13), this information is not sufﬁcient to
estimate topical bioavailability. The algorithms available are
87 0724-8741/08/0100-0087/0 # 2007 Springer Science + Business Media, LLC
Pharmaceutical Research, Vol. 25, No. 1, January 2008 (# 2007)
DOI: 10.1007/s11095-007-9429-7
1School of Pharmaceutical Sciences, University of Geneva, 30 quai
E. Ansermet, CH-1211, Geneva 4, Switzerland.
2Debio Recherche Pharmaceutique S.A., Route du Levant 146, CH-
1920, Martigny, Switzerland.
3Antares Pharma AG, Gewerbestrasse 18, 4123, Allschwil, Switzerland.
4Universite ´ catholique de Louvain, Unite ´ de pharmacie gale ´nique,
industrielle et ofﬁcinale, Avenue E. Mounier 73, 1200, Brussels,
Belgium.
5UCB SA, Chemin du Foriest 1, 1420 Braine-l’Alleud, Belgium.
6Department of Pharmacy & Pharmacology, University of Bath,
Claverton Down, Bath, BA2 7AY, Allschwil, UK.
7To whom correspondence should be addressed.(e-mail: r.h.guy@
bath.ac.uk)able to approximate a value for the maximum drug ﬂux across
the skin, but cannot quantify the potential impact of particular
vehicles (or vehicle constituents) on skin barrier function (14).
Equally, these calculations assume that the thermodynamic
activity of the drug remains constant during the application
period, a situation which does not pertain, of course, when one
or more formulation component is volatile (15) or the dose
administered is very small (i.e., a ﬁnite dose situation).
It follows that an experimental approach is necessary,
and the objective of this review is to evaluate different
techniques currently under consideration. We begin with a
discussion of the different procedures which are accepted by
the regulatory authorities at this time, and which contribute
to the approval of innovative, and/or generic, topical drug
products.
CURRENT OPTIONS FOR TOPICAL
BIOAVAILABILITY/BIOEQUIVALENCE
ASSESSMENT
As mentioned above, for topical dermatological prod-
ucts, pharmacokinetic measurements in blood, plasma or
urine are usually not feasible because of the very low
concentrations achieved in these typical sampling compart-
ments. There is also debate as to whether measurable levels
in the blood (when detectable), for example, are relevant to
local, topical drug bioavailability. On the other hand, the
cumulative amount of drug reaching the systemic circulation
is pertinent with respect to potential toxicity and may
indicate the need to limit topical application to avoid
undesirable side-effects.
For certain topical drugs, speciﬁcally the corticosteroids,
pharmacodynamic measurements represent an accepted
approach with which to establish bioequivalence between
different formulations (and are used, as well, in the develop-
ment of new chemical entities in the same therapeutic class).
These drugs produce skin blanching at the site of application
and this response has been correlated with clinical efﬁcacy
(16). The original Stoughton–McKenzie vasoconstriction
assay (17) employed visual evaluation of the degree of
blanching by trained observers. As this approach is rather
subjective (18), it is now considered sensible to use a
chromameter to quantify the blanching response (19–22).
This method has been reviewed in detail elsewhere (20).
While the advantages of the vasoconstriction assay for
topical steroids are clear, the approach has the obvious
limitation that it cannot be applied to all drugs. Indeed, the
literature contains very few other examples in which phar-
macologic response has been used to assess topical drug
availability. Evaluation of vasodilatation provoked by nico-
tinic acid esters, and its inhibition by anti-inﬂammatory
drugs, has been performed using laser Doppler velocimetry
and chromametry (23–27). The reduction in erythema
induced by topical ibuprofen has been correlated with drug
levels in the epidermis (27). Equally, topical retinoids have
been shown to provoke increases in transepidemal water loss
in a time- and dose-dependent fashion (28–30), although the
generality of this effect has not been established (29).
It follows that, at the present time, topical drug
bioavailability and bioequivalence must be assessed via
clinical studies, which are typically costly and time-
consuming (31); regulatory agencies have therefore been
seeking alternative methodologies, especially for bioequiv-
alence studies to ease the burden on those attempting to
commercialize useful products at competitive prices. While
much debate has centered on the potential of different in
vitro techniques, in particular the use of Franz diffusion cell
studies to compare different formulations, these methods
have not been accepted as useful contributors to the overall
determination of bioavailability and bioequivalence. Cur-
rently, the relevance, reliability and reproducibility of the in
vitro approach have not been demonstrated to the level
necessary for the regulatory bodies; major concerns centre
around the source and supply of human skin tissue, the
Fquality-control_ of the experiments, in general, and the
absence of an effective clearance mechanism for drugs
(especially lipophilic species) from the membrane. Only
for demonstrating the benign effect of minor formulation
changes are in vitro experiments, using model, polymer
membranes, authorized by, for example, the US Food and
Drug Administration.
Nevertheless, there remains a real need to develop valid,
effective and economical approaches with which to measure
topical drug bioavailability, not least for the evaluation of
bioequivalence when generic products are submitted for
marketing approval. The remainder of this review examines,
primarily, two methodologies currently under close examina-
tion for the measurement of topical bioavailability and
bioequivalence: namely, the tape-stripping and microdialysis
techniques.
TAPE STRIPPING
Tape stripping involves sequentially removing micro-
scopic layers (typically 0.5–1 mm) of stratum corneum. It is
usually performed by placing an adhesive tape-strip onto the
skin surface, followed by gentle pressure to ensure a good
contact, and subsequently removal by a sharp upward
movement. The procedure is relatively painless and non-
invasive, given that only dead cells (corneocytes) embedded
in their lipid matrix are removed. Even if skin stripping
remains a form of environmental insult, a homeostatic repair
response in the epidermis is rapidly elicited (32) which results
in rapid restoration of barrier function (33).
Tape stripping is used in various ﬁelds of cutaneous
biology: for example, to evaluate the barrier function (34), to
investigate dermatopathologies such as inﬂammatory or
neoplastic disorders or xerotic conditions (35), to monitor
gene expression (36,37), to investigate pH proﬁles (38), to
evaluate animal skin as a surrogate for human skin (39), to
induce Toll-like receptor 9 expression (40) and so on (41). In
dermatopharmacology, tape stripping is used to assess
cutaneous drug or excipient levels in the skin after topical
dermatological treatment, either in the removed tape-strips,
or directly in the tape-stripped skin. It follows that tape
stripping is a particularly useful technique to assess the local
bioavailability of drugs whose target site is the SC itself (such
as antifungal agents (43–46), UVA/UVB ﬁlters (47–51)o r
antiseptics (52).
The tape stripping technique may also offer a real
alternative for local bioavailability and/or bioequivalence
assessment of topically applied dermatological agents whose
88 Herkenne et al.target is the underlying viable tissues. As the SC is usually
the principal resistance to the penetration of topically applied
compounds (4), it has been argued that drug levels in the
barrier should be correlated with those attained in the
underlying, viable components of the skin, i.e., the sites at
which many dermatological diseases are manifest.
This hypothesis was tested, but only partially validated,
by Rougier et al. (53–56). In both animal models and human
volunteers, for a range of compounds (mostly low molecular
weight, low lipophilicity) delivered from several different
formulations, the amount of active in the SC after a 30-min
application, and subsequent removal of any remaining
vehicle, was determined by tape-stripping. At a contra-lateral
position, the same 30-min application and cleaning procedure
was adopted but, rather than tape-stripping the SC, the
penetration of chemical taken up into the skin was quantiﬁed
by its urinary excretion over the next 4 days. Good
correlation between the two measurements was achieved
(see Fig. 1) suggesting the value of the tape-stripping
approach for a simple and rapid determination of potential
systemic exposure. However, the experiment only solves part
of the bioavailability challenge: it provides a measurement of
the extent of absorption but gives no information on rate. As
such, in its originally developed form, the so-called Rougier
technique is not suitable for regulatory use.
An alternative strategy to test the hypothesis is to
demonstrate correlation between drug levels measured in the
SC by tape-stripping and a pharmacodynamic effect in the
skin. This has been accomplished in some necessarily limited
studies using (a) hydrocortisone (57) and betamethasone
diproprionate (16,20), the pharmacological activity of which
was assessed by skin blanching, (b) miconazole and ketoco-
nazole, the efﬁcacy of which against C. Albicans in vitro was
determined (42), and (c) iododeoxyuridine, for which clinical
efﬁcacy in reducing lesion severity was evaluated (58).
Ultimately, of course, these types of validation studies are
essential if a tape-stripping approach is to be adopted for
routine bioavailability and bioequivalence assessment. For
the moment, however, the ﬁeld is (appropriately) examining
how to optimize the tape-stripping procedure so as to extract
the maximum information from the experiment in the most
efﬁcient manner possible. These advances are now discussed
in detail.
Method Development and Optimization
Sequential tape-stripping of the stratum corneum allows
horizontal fractions of the membrane to be obtained. The
tape-strips must then be extracted to recover and quantify
the absorbed drug. Local bioavailability may be assessed
either from the combined tape strips, or from the individual
tape-strips. The method of quantiﬁcation depends, of course,
on the nature of the drug and the amount present on the
tape-strips. Various approaches have been used ranging from
UV-VIS spectrophotometry (59) to the more ubiquitous
HPLC (with UV, ﬂuorescence, or even mass spectrophoto-
metric detection), gas chromatography (60–62), scintillation
counting (42,57,63) and infrared spectroscopy (64–67). The
key criteria are that the extraction process does not degrade
the drug, that it is efﬁcient and reproducible, and that it is
free from interference from components of the SC and/or the
tape adhesive. Quantiﬁcation of the drug in the combined
tape-strips enables the total amount in the stratum corneum
to be determined.
After much discussion (31,68–71), a draft guidance was
published by the US Food and Drug Administration (FDA)
in 1998 (21) in which the general procedures for conducting a
bioavailability/bioequivalence study were described. Brieﬂy,
the guidance proposed the following steps:
1. After application of a drug product for a given
application time, excess formulation was to be removed
by an appropriate (but not speciﬁed) procedure.
2. Two sequential tape-strips of the SC were to be taken
and discarded, the guidance arguing that material
located on these samples had not been, and would not
be, absorbed.
3. Subsequently, ten strips from the application site were
to be made, combined and extracted with a suitable
solvent.
4. The entire process was to be performed at multiple
sites following different times of application (absorp-
tion phase, Fig. 2a) and different periods between the
longest application time and the time at which
stripping was performed (elimination phase, Fig. 2b).
5. The total amount of drug in the SC was then to be
displayed as a function of time as a so-called
dermatopharmacokinetic (DPK) proﬁle, character-
ized by a maximum amount, the time at which this
maximum was achieved, and an Farea-under-the-
curve_ (Fig. 3).
6. Simultaneous comparison of two formulations of the
same drug would allow an assessment of local bio-
equivalence using the representative DPK parameters.
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Fig. 1. Correlation between the amount of different chemicals
absorbed across skin following a 30-min application and the quantity
recovered in SC tape-strips after an identical, but independent,
administration procedure. Redrawn from (52).
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was open to a number of criticisms, and exposed some clear
ﬂaws. In brief, while many of these problems have now been
recognized, but not fully resolved, the document has there-
fore been withdrawn and, at the time of writing, the
possibility of a reﬁned version being developed is under
examination. Among the weaknesses of the original guid-
ance, one may cite, in particular:
(a) The timing of the tape-stripping procedures during
the absorption and elimination phases is not clearly
delineated and (apart from trial-and-error) no
rational approach to their determination is offered.
(b) The number of tape-stripping procedures is consider-
able, rendering a DPK evaluation onerous in terms of
the work involved (despite the fact that Fpooling_
tapes for analysis does partly reduce this burden).
(c) The unvalidated discarding of information from the
ﬁrst two tape-strips has never been subjected to
rigorous examination; indeed, it has been argued
that these data are relevant to a complete bioavail-
ability assessment (46).
(d) Ten tape-strips do not remove the same amount of
SC from all subjects (or even, potentially, within a
subject, especially if one of the formulations being
compared contains an excipient which weakens SC
cohesivity). As a result, drug will be measured in
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Fig. 2. Schematic representation of a dermatopharmacokinetic (DPK) study to assess topical bioequivalence between test and reference
formulations containing the same drug. a In the uptake, or absorption, phase, the SC is tape-stripped immediately after each treatment time,
and the drug level in the barrier is determined. b In the clearance phase, after the maximum treatment time, the SC is subsequently stripped
after progressively longer periods post-removal of the formulations. CTR=control, drug-free formulation.
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Fig. 3. DPK proﬁles of reference and test formulations containing
the same drug. The parameters to be compared are the maximum
drug level in the SC (Cmax), the time at which this maximum level is
reached (Tmax) and the area under the SC quantity versus time
proﬁle (AUC).
90 Herkenne et al.different Fvolumes_ of the matrix, rendering compar-
isons between different treatments/subjects essen-
tially meaningless.
Nevertheless, there have been some reports of success
using the DPK procedure as outlined in the FDA guidance
(or at least part of it); one particularly good example showed
a correlation between both the area-under-the-curve and
maximum concentration parameters and the clinical efﬁcacy
of tretinoin gels (Fig. 4 (72)). Less encouraging, and ulti-
mately responsible for the DPK guidance_s withdrawal, was
an inter-laboratory comparative study (again using tretinoin)
that resulted in diametrically opposite conclusions about the
bioequivalence of different formulations (73–75).
The outcome of this initial work has been a serious re-
evaluation of the overall worthiness of the approach and an
ongoing examination of how it may be improved. The need
to quantify (or, at least, to have some idea of the amount of)
the SC removed is now clear, not only for the reasons already
given, but because it is obvious that different tapes and
different experimentalists will inevitably strip the SC in a
variable fashion, making inter- and intra-laboratory compar-
isons impossible. Even when the type of tape is standardized,
and an attempt is made to exert an equal pressure on each
tape applied to the skin (76), the SC amount removed still
depends on, for example, the speed with which the tape is
subsequently removed from the subject and exactly where on
the forearm the experiment is performed. As standardization
appears very difﬁcult to achieve, therefore, it is clearly more
sensible to identify a method by which the SC removed can
be quantiﬁed, thereby allowing the uptake of drug into this
tissue to be normalized (and expressed, for example, as an
amount per unit volume, or per unit weight, of SC). For the
moment, these uncertainties mean that the minimum number
of subjects required for a bioequivalence study cannot be
speciﬁed.
Another, but more invasive (and probably less accept-
able) option is to use a procedure which removes all the SC
at once. In this case, cyanoacrylate adhesive is applied to a
glass slide which is then pressed ﬁrmly to the skin for about
30 s. Subsequent removal in one quick movement removes
essentially all of the SC in one complete sheet (77,78).
However, validation of the method for bioavailability/bio-
equivalence studies has not been reported.
Various approaches to quantify the SC amount removed
have been considered but, at this time, no single method has
achieved universal acceptance. The most straightforward
procedure (and, in fact, the one needed to calibrate all
others) is to weigh each tape-strip before and after SC
removal and to determine the amount (m) of tissue removed
from the difference between these weights. As the area (A)
of SC stripped is known, and the density (r) of the tissue has
been published (5), it is possible to convert the SC weight
into a depth, or distance (x), into the barrier: x=m/(AIr).
Additional standardization is then possible by including in
the experimental design, concomitant measurements of
transepidermal water loss (TEWL) during the tape-stripping
process (this can be performed either at the drug product
application site, or at a position adjacent to the treated skin
when the formulation contains volatile or occlusive excipients
that can interfere with the TEWL measurement). Baseline
TEWL (TEWL0) across unstripped SC of thickness L is given
by Fick_s ﬁrst law of diffusion:
TEWL0 ¼
D   K
L
$C ð1Þ
where D and K are the diffusion coefﬁcient of water in the
SC, and the SC-viable tissue partition coefﬁcient of water,
respectively, and DC õ1g Icm
j3. After tape-stripping has
removed a depth x of SC, the TEWL will have increased to a
new value given by:
TEWLx ¼
D   K
L   x ðÞ
$C ð2Þ
Inversion of this second expression yields a linear relationship
between (TEWLx)
j1 and x, and the intercept of this line on
the x-axis equals the SC thickness (L)( F i g .5 (79)).
With this information in hand, all SC stripping data can
now be expressed, not in terms of Bamount per ten strips,^ or
even as amount per volume of SC, but as an amount per
normalized fraction of SC removed (x/L), a strategy which
allows results from disparate subjects of different SC thick-
nesses to be rationalized (Fig. 6 (80)). While this appears to
be a sensible, general solution to the problem, it is important
to point out one caveat: as the tape-stripping procedure and
the TEWL measurements require a ﬁnite amount of time,
analysis of the data for rapidly permeating compounds may
be complicated by the fact that the time to obtain the tape-
strips, and to record the changes in TEWL, may be similar to
the application time, and the drug_s concentration gradient
may therefore shift during the data collection process (65).
Other methods to quantify the SC removed by tape-
stripping have been proposed and demonstrated. Clearly, the
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Fig. 4. DPK proﬁles (means of n=49) of three (0.025% v/v) tretinoin
gel products in human stratum corneum (SC). Solid line=reference
product (Retin-A); dotted line=generic formulation; dashed line=A-
vita gel (redrawn from (72)). At the time points indicated with an
asterisk (*), a signiﬁcant difference between Avita and both the
reference and gel products exist (analysis of variance, Fisher_s
protected least signiﬁcant difference, p<0.05).
91 In Vivo Methods for the Assessment of Topical Drug Bioavailabilitygravimetric approach is not without problems (static electric-
ity on the tapes, misleading weights due to uptake of
formulation excipients, small amounts of SC removed,
tediousness, etc.) and a more direct assessment would be
useful. Progress has been made both with respect to the use
of a protein assay to quantify keratin on the tapes, and via a
spectrophotometric method evaluating the scattering/absor-
bance of UV/visible radiation; the latter procedure also has
the potential to quantify drug on the tape-strip, assuming that
an absorbance band distinct from those of the SC can be
identiﬁed. Both techniques have the potential to be more
Fhigh-throughput_ once sufﬁciently optimized; however, for
the moment, neither approach has been perfected, rejection
of individual data has not been eliminated, and both rely
upon the Fgold standard_ weighing measurement for calibra-
tion (81–86). Another option, which deserves a ﬁnal word in
this context, is the application of infrared spectroscopy (IR),
particularly its use in vivo via the attenuated total reﬂectance
(ATR) mode. In this approach, it is possible to semi-
quantitatively assess an IR-active drug (assuming there is at
least one absorbance within its IR spectrum distinct from
those in that of the SC) either on a series of tape-strips or in
the outermost micron or so of SC which has not yet been
stripped from the skin (44,45,87–91) (Fig. 7).
T h em e t h o dh a so f t e nb e e na p p l i e dt oam o d e l
permeant, 4-cyanophenol (the CKN (nitrile) absorbance from
which is particularly intense and occurs at a frequency where
the SC is essentially IR-transparent (64–67)), and also to
other more relevant substances such as the anti-fungal drug,
terbinaﬁne (45). The IR spectrum of SC also contains
information about the amount of endogenous lipid and
protein present as a function of depth into the barrier (92),
although this feature has not been explored as a potentially
simple approach to quantify the amount of tissue removed on
each tape-strip. Recent developments in IR imaging coupled
with ATR, and the application of chemometrics to better
Btease out^ spectral information, may prove to be useful
avenues for further research in this regard (93). However,
even supposing the existing limitations can be overcome, the
principal weakness of IR remains: namely, its relative
insensitivity compared (for example) to analysis of extracted
tape-strip samples by HPLC.
Interpretation of Tape-Strip Data
When drug and SC are quantiﬁed on each tape-strip
removed post-treatment of the SC, and TEWL measurements
have been made to determine SC thickness, it is possible to
displaythe concentrationofthepermeant(Cx) as a function of
its relative depth (x/L) into the barrier (Fig. 8). Assuming
Fickian diffusion and the following boundary conditions:
& the Fdose_ of the drug applied is inﬁnite—that is, the
drug concentration in the vehicle (Cv)r e m a i n s
constant throughout the application time (t)
& the SC initially contains no drug (Cx=0 at t=0)
& the viable skin provides a Fperfect sink_ for the
penetrating drug (Cx=0 at x=L for tQ0)
then the proﬁle is given by (46,64,94):
Cx ¼ K   Cv 
1   x=L
  
  2= 
X 1
n¼1
1=nsin n    x=L
  
  exp  D   n2    2   t 
L2
  
()
ð3Þ
where K is the SC-vehicle partition coefﬁcient of the drug
and D is its diffusivity through the barrier. When data like
those in Fig. 8 are ﬁtted with the above expression, it is
possible to derive two parameters, K and D/L
2,w h i c h
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Fig. 5. a Progressive increase of transepidermal water loss (TEWL) as a function of the absolute depth (mm) of stratum corneum removed.
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92 Herkenne et al.characterize drug uptake into the SC from the applied
formulation. These physicochemical parameters are relevant
to DPK in that they report, respectively, on the extent and
the rate of drug uptake into the SC: the partition coefﬁcient
(K) reﬂects the relative afﬁnity of the drug for the SC
compared to the applied formulation and is related to the
extent of absorption, therefore; the ratio D/L
2 has units of
(time)
j1 and can be considered as a ﬁrst-order rate constant
for drug transport through the SC—a measure of absorption
rate, in other words. Integration of the concentration proﬁle
equation yields an Barea-under-the-curve^ (AUC (46)):
AUC ¼
Z1
0
Cxd x=L
  
¼ K   Cv
1
2
 
4
 2
X 1
n¼0
1
2n þ 1 ðÞ
2 exp  
2n þ 1 ðÞ
2    2   D   t
L2
 ! ()
ð4Þ
which represents the total amount of drug in the SC at the
end of the application period (t). Together, K, D/L
2 and AUC
offer DPK parameters that can be used to objectively compare
topical drug bioavailabilities from different formulations. They
also allow differences in bioavailability to be explained
mechanistically; for example, to answer the question whether
a putative penetration enhancer elicits improved drug delivery
by increasing partitioning into, or by facilitating diffusion
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is deﬂected by a ﬁrst mirror to the ATR crystal, in which it undergoes
total internal reﬂection, penetrating superﬁcially into the skin, before
exiting the crystal and being re-directed to the detector.
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Fig. 8. Terbinaﬁne (TBF) concentration versus SC depth proﬁles in
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(EtOH-IPM, 50:50), and b in the same formulation containing 5%
oleic acid. Redrawn from (46).
93 In Vivo Methods for the Assessment of Topical Drug Bioavailabilitythrough, the barrier. This capability has been illustrated using
the anti-fungal drug, terbinaﬁne (Fig. 8 (44)).
Finally, it is worth pointing out that once K and D/L
2
have been evaluated from an experimentally determined Cx
versus x/L proﬁle, they can be used with the equation above
to predict AUC at all other times of application (t). Providing
that the parameters do not change with time [which, it must
be admitted, is not always the case (45)], this means that the
complete absorption proﬁle of the drug can be derived from a
relatively short-duration experiment. Again using terbinaﬁne,
some preliminary validation of this idea has been achieved
[Table I (46)]. A more extensive effort, with ibuprofen as the
delivered drug, has conﬁrmed this earlier ﬁnding (94). In
addition, this data analytical approach has value with respect
to experimental design; with knowledge of D/L
2, the classic
lag-time for diffusion (L
2/6D)a c r o s st h eS Cc a nb e
calculated, as well as the time necessary to reach steady-
state transport (õ2.7IL
2/6D (95)). This information should
permit more efﬁcient DPK studies to be performed with
tape-stripping timed to provide the maximum possible
discrimination, for example, between the different drug
products under evaluation.
Tape-Stripping—Unresolved Issues
Despite the clear value of a DPK approach based upon
tape-stripping, there remains work to be done before its
usefulness can be fully exploited. First and foremost, the
method has to be validated appropriately via clear demon-
strations that signiﬁcant differences in drug uptake into
normal SC translates into clinically distinguishable scenarios
in the real world; that is, the hypothesis that the SC
concentration proﬁle reﬂects drug availability at the site of
action must be conﬁrmed. Logically, this will be more
straightforward to accomplish with drugs having their site of
action on or in the SC (e.g., anti-fungals), and it is likely that,
at least initially, the case will have to be made on a drug class
by drug class basis. Although it is clearly expedient to move
quickly to an easier approval path for generic topicals, the
value and relevance of any approach adopted must be
recognized by the dermatologist and must be seen to
translate into a measurable clinical outcome.
Second, the procedures to be followed, and the DPK
protocol itself, have to be at least partially standardized.
Quantiﬁcation of the SC removed is mandatory and there is
an important need to develop a simple and rapid method for
this purpose. With such knowledge, complete removal of the
SC is not necessary for comparative purposes, thereby
allowing for a less invasive procedure; further, this means
that the method does not have to be restricted to one
particular adhesive tape, the choice of which can be based on
methodological criteria such as ease of drug extraction,
absence of components that may potentially interfere with
the drug assay, and allowing removal of the SC with a
reasonable number of strips (õ10–15). Cleaning the treated
area of the SC prior to tape-stripping is important and must
be capable of removing excess formulation efﬁciently without
inadvertently Fdriving_ drug into the barrier. This includes
displacement of vehicle from the natural Bfurrows^ in the
skin (91), the depth of which can be signiﬁcantly greater than
the SC thickness. Debate continues as to whether one or two
tape-strips should be taken initially and discarded, the
argument being that any drug lodged on these layers, even
after cleaning the skin, would never be absorbed. For the
moment, no consensus exists on this point but clearly it will
be necessary to better deﬁne the procedures to be followed
when cleaning the skin at the end of the application period.
This issue is particularly important both for poorly penetrat-
ing chemicals (e.g., those of higher molecular weight) and for
drug products administered in complex vehicles (such as
those including liposomes or nanoparticles).
Third, the question of spatial localization of drug must
be addressed; speciﬁcally, it has been recognized that the
target for certain drugs may be a skin appendage (a hair
follicle, or a sebaceous gland, for instance) and that particular
formulations have been proposed for optimization of delivery
to these structures. Exactly how tape-stripping might be used
to compare vehicles which set out to achieve, for example,
follicular targeting, has not been demonstrated. In this case,
it would be necessary to show that SC levels are correlated
with drug amounts in the appendage; however, if a formula-
tion did speciﬁcally target a follicle, it might be logical to
think that one would ﬁnd less drug in the SC as a result. The
problem is complex, therefore, and may need to call upon
application of recent work which has attempted to deduce
the contribution of follicular transport to total drug delivery
by comparing SC uptake in normal skin to that in skin whose
follicles have been physically sealed (96–99). Obviously,
further validation is required using drugs and drug products
designed to act on these appendageal structures.
Finally, there is the question of the relevance of the
DPK approach, which has been developed for use on normal
skin, to drug performance on diseased skin. In part, this
relates to the validation issue discussed above and the need
to correlate DPK measurements with clinical outcome. There
is also the outstanding unknown as to whether DPK, or a
modiﬁed version thereof, can be adopted for use on diseased
tissue. It is important to acknowledge, furthermore, that the
methodology in its present state does not differentiate free
and bound drug in the SC.
MICRODIALYSIS
During the last decade, microdialysis has been shown to
be a promising technique for the assessment of cutaneous
drug delivery (100,101). The technique is based on the
passive diffusion of compounds down a concentration gradi-
Table I. Comparison Between the Experimentally Determined
Values of AUC (meanTSD; n=4) Following 2 and 4 h of Terbinaﬁne
Application, and the Predictions Based Upon K and D/L
2 Results
Determined from the Data Obtained after a 30-min Application
Treatment time (h)
Experimental
AUC 10 (M)
Predicted
AUC 10 (M)
0.5 2.60T1.09 –
2 4.28T1.81 4.76T1.95
a
4 4.17T1.03 5.21T2.68
a
Data from [45].
aExperimental value is not signiﬁcantly different (p>0.05) from the
corresponding predicted result.
94 Herkenne et al.ent across a semi-permeable membrane forming a thin
hollow Btube^ (typically a few tenths of a millimetre in
diameter), which—at least, in theory—functionally repre-
sents a permeable blood vessel. Two kinds of probe are in
common use: the so-called linear and concentric probes
(Fig. 9). The former is the most prevalent design used
because it is simple, thinner and inexpensive to manufacture
from artiﬁcial kidney ﬁbres (102–104). The probe is
implanted superﬁcially into the dermis or subdermis, parallel
to the skin surface via a guide cannula. The ﬁbre is slowly
perfused with a physiological solution, which equilibrates
with the extracellular ﬂuid of the surrounding tissue, ex-
changing substances smaller than the cut-off value of the
membrane. The exchange of material is driven by passive
diffusion (105), and the microdialysis technique may be used
not only to monitor the extracellular concentrations of
exogenous or endogenous compounds, therefore, but also to
deliver drugs to a speciﬁc target tissue.
A key feature of microdialysis is its ability to continu-
ously monitor the extracellular concentration of a drug in
different compartments of the body. Indeed, a microdialysis
probe can be implanted in virtually any body organ or tissue
(106). Among the limited number of techniques available for
the direct assessment of drug concentrations in dermis,
cutaneous microdialysis is the only one that allows unbound
analytes to be sampled. Hence, microdialysis provides a
pharmacokinetic proﬁle, with high temporal resolution, of
the drug in the target tissue. As the level of unbound drug
generally determines the pharmacodynamic response, the
pharmacological relevance of the method is clear (Fig. 10).
The feasibility of microdialysis to sample a drug in the
skin has been demonstrated in animals and humans (101,107).
Microdialysis has been shown to be useful (a) to assess free
drug concentrations in the dermis or subcutaneous tissue,
depending on probe depth, after topical application of a
formulation, (b) to compare different formulations of a drug
and assess bioequivalence/bioavailability, and (c) to measure
whether therapeutic concentrations are reached in the skin.
Another important advantage of microdialysis is that no
biological ﬂuid is removed. In vivo, in man, multiple sampling
sites can be simultaneously set up and used to determine, for
example, drug penetration into the skin and the effect of
different vehicles (107), cutaneous metabolism (108,109), and
the impact of barrier disruption (110). This same ﬂexibility
has also allowed the impact of probe depth on the data
obtained to be assessed (111,112), and has allowed the
inherent variability of the method to be reduced (113).
The initial research evaluating microdialysis for topical
delivery was mostly performed in rats, an animal chosen for
its ease of handling rather than for its suitability as a model
for human skin penetration. Proof-of-concept was established
with 5-ﬂuorouracil (103), and subsequent work evaluated,
inter alia, the impact of formulation, the action of penetra-
tion enhancers, and the improved delivery possible with
iontophoresis (111,112,114–122)). A signiﬁcant effort has also
been made to correlate microdialysis recovery with barrier
perturbation. Using salicylic acid as a model penetrant,
uptake was shown to be proportional to barrier function as
measured, for example, by transepidermal water loss (123),
suggesting that the technique might be useful for assessing
bioavailability in topical dermatoses.
In humans, the ﬁrst applications of microdialysis in-
volved the measurement of (a) ethanol absorption (124), and
(b) cutaneous glucose levels (125,126). Subsequently, the
transdermal delivery of nicotine released from a commercial
patch has been investigated (127,128), and some correlation
has been found between the plasma concentration and
formulation 
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Fig. 9. Schematic diagram of two currently used microdialysis probes
for DPK experiments. In both cases, a semi-permeable dialysis
membrane collects the absorbed free drug. a Single-lumen probe: the
membrane is located in the middle of the probe, and the perfusate
ﬂow is mono-directional. b Dual-lumen probe: the membrane is on
the tip of the probe, and the perfusate ﬂow is bi-directional.
Fig. 10. Penetration of lidocaine from three different formulations into
the dermis of eight volunteers measured by microdialysis (from (107)).
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obtained with estradiol, however, with eight out of ten
experiments revealing no detectable estradiol in the dialy-
sate. Likewise, even after barrier disruption, betamethasone
17-valerate, and the highly protein-bound drug, fusidic acid,
could not be successfully sampled (129). On the other hand,
less hydrophobic and more quickly penetrating substances,
such as non-steroidal anti-inﬂammatory drugs, have been
monitored easily by cutaneous microdialysis (108,109,111,
130–132). The cutaneous penetration of salicylic acid through
normal and perturbed skin using microdialysis sampling has
been shown to be more sensitive than non-invasive bioengi-
neering techniques in detecting the effect of acetone treat-
ment. A positive dose–response was also found between
salicylic acid penetration and the degree of irritant dermatitis
induced by sodium lauryl sulphate pre-treatment.
The skin penetration of various salicylate esters and
their skin metabolism in dermal and subcutaneous tissue has
been studied (109). The delivery of topical diclofenac was
similarly demonstrated following a single application of a gel
(130). The topical bioequivalence of lidocaine delivery from
a microemulsion and from a conventional oil-in-water
emulsion was assessed pharmacokinetically by microdialysis
and the results were compared to pharmacodynamic mea-
surements as well (107). Furthermore, microdialysis has been
used to study iontophoretic delivery of propanolol, acyclovir
and ﬂurbiprofen (111,133,134). Additionally, the role of
stratum corneum, and of dermal microvasculature perfusion,
in the penetration and tissue distribution of the water-soluble
drugs, acyclovir and pencyclovir, have been investigated by
cutaneous microdialysis (135).
Microdialysis is claimed to be minimally invasive,
provoking only a minor, reversible trauma caused by
insertion of the guide cannula when implanting the probe
(136–138). Moreover, changes in the tissue surrounding the
probe may affect the recovery and measurement of the
analyte. Therefore, when using the microdialysis technique,
an equilibration of 60–90 min following probe insertion is
usually an integral part of the protocol (136,137). The effects
of the probe insertion can be classiﬁed as (a) direct trauma to
cells and tissues; (b) modiﬁcation of blood perfusion due to
an axon reﬂex; and (c) inﬂammatory or Bforeign body^
reactions to the probe (139). In vivo assessment of the skin
after insertion of the microdialysis probe is usually performed
using non-invasive measurements of TEWL, cutaneous blood
ﬂow, and histology (136–139). The extent and duration of
Btrauma^ to the skin can be modulated by the probe design
and the use of a local anaesthetic. Guide cannulas with
smaller dimensions generally provoke smaller reactions and
the provoked increases in local blood ﬂow (and histamine
release) subside more quickly; the concomitant use of a
topical anaesthetic cream can reduce the duration of vascular
response to less than an hour (140–142). Longer-term
implantation has been studied in animal models and a
general inﬂammatory response observed: inﬁltration of
lymphocytes at 8 h, cell changes and cell attachment to the
dialysate membrane at 24 h, ﬁbrosis after a week, and scar
tissue formation. However, apart from the initial reaction on
probe insertion, tissue responses are relatively minor
throughout the duration of a typical microdialysis experiment
(õ8h( 103,138,143)).
Method Development and Optimization
Since microdialysis operates under non-equilibrium con-
ditions, the concentration of analyte in the dialysate is lower
than that in the extracellular ﬂuid surrounding the probe.
Relative recovery has been deﬁned as the ratio of these
concentrations, and should be independent of the absolute,
free concentration of the compound in the skin (assuming no
binding to the dialysis membrane). Several approaches have
been suggested for determination of the in vivo recovery of
the analyte by the microdialysis probe: the stop-ﬂow method
(144), the extrapolation-to-zero ﬂow technique (142), the
point of no net ﬂux (102), and retrodialysis (145). Extensive
reviews of the various techniques have been published (105).
Retrodialysis is probably faster and more convenient than
the other alternatives. This, Binternal reference technique^
(146,147), introduces a marker into the perfusate and the rate
of delivery of this compound is measured during the micro-
dialysis experiment. Recovery (R) is then determined from:
R ¼ 100   Cin   Cout ðÞ =Cin ð5Þ
where Cin is the concentration of marker perfused into the
ﬁbre and Cout is the concentration determined in the sample.
This method assumes, and/or demonstrates, that the recovery
efﬁciency of the target analyte is quantitatively similar to the
delivery of the retrodialysis marker. It follows that the
marker should physicochemically resemble, as far as possible,
the analyte of interest. An important advantage is that
ﬂuctuations in the recovery of the probe during the experi-
ment are taken into account by continuous retrodialysis of
the marker. Conversely, a signiﬁcant limitation is that the
presence of the marker perturbs in some way (e.g., compe-
tition for binding) the local disposition of the drug.
The relative recovery is inﬂuenced by the probe, the
tissue perfused and the analyte of interest (100). To increase
the relative recovery, the length of the probe and its
molecular weight cut-off limit should be increased, while
perfusate ﬂow should be reduced. Typically, in dermal micro-
dialysis, the probe length is õ1–2 cm, and the ﬂow rate
between 0.5and 5ml/min.The molecularweight cut-off chosen
is typically in the range of 5–20 KDa to avoid protein leakage
into the dialysate. For dermal microdialysis, the linear probe
design is preferred whereas, for subcutaneous implantation,
both linear and concentric probes have been used.
Because the dialysis ﬁbre excludes diffusion of proteins,
the samples are sufﬁciently puriﬁed for further analysis. The
principal challenge to the procedure is sensitivity, especially
for the measurement of (a) lipophilic permeants which are
slowly and poorly extracted into the microdialysis perfusate,
and (b) compounds with high protein binding. For example,
in earlier work, fusidic acid and betamethasone-17-valerate
were not detectable by microdialysis (129). Although it has
been suggested that recovery may be improved by introduc-
ing co-solvents (e.g., polyethylene glycol), or cyclodextrins,
or lipids, into the perfusate, or by changing its pH, the
advantages of such a strategy must be balanced against
potential tissue alterations and their impact upon biocom-
patibility (148,149). Low rates of perfusion (0.5–5 ml/min) are
mandatory for compounds with low recoveries, especially
those which are highly protein-bound. Nevertheless, this
96 Herkenne et al.means that the samples are of low volume and contain small
absolute amounts of analyte. The analytical challenge is
therefore considerable and demands sensitive techniques;
HPLC may not be sufﬁcient and the use of speciﬁc biosensors
and mass spectrometry (as well as other techniques) has been
reported (138,150).
To validate the use of microdialysis, as a method to
assess bioavailability/bioequivalence, a systematic compari-
son with existing methods is essential. Generally speaking,
when different formulations of a drug have been compared,
microdialysis has determined the same rank order as other
approaches. However, the absolute, measured amounts of
drug absorbed are different (Fig. 11). For example, the
quantity of drug found in the skin after an in vitro diffusion
cell experiment is higher than that detected by microdialysis
(103). The explanation for this observation is that the classic
in vitro technique (a) measures both bound and unbound
drug, and (b) does not reproduce the effects of local blood
ﬂow on absorption.
A particularly positive, and rather unique feature, of
microdialysis is that the method can be used to evaluate drug
permeation across both normal and diseased skin. Further-
more, in the same psoriatic patient, penetration at a speciﬁc
lesion may be compared to that through unaffected skin. In
addition, as well as measuring drug concentration, micro-
dialysis may also have the potential to quantify a biomaker,
or the concentration of another surrogate measure, for
therapeutic activity. Concomitant pharmcokinetic and phar-
macodynamic evaluations are therefore possible.
Interpretation of Microdialysis Data
It should be emphasized that data from microdialysis
experiments can be analyzed to yield practical pharmacoki-
netic parameters. Cmax, Tmax, absorption constant, lag time
and AUC can be determined from the plot of free drug
concentration in the dermis as a function of time. For
example, a one-compartment model has been used to
differentiate between results from two formulations of
lidocaine (107) via comparison of absorption rates and lag-
times. In this case, prilocaine was used as a retrodialysis
calibrator. In another elegant study, cutaneous microdialysis
demonstrated that the skin/plasma ratio of 8-methoxypsor-
alen was orders of magnitude greater following topical
administration of the drug (as compared to oral dosing).
Evaluation of Cmax in the skin, furthermore, permitted
optimization of the time of UV irradiation in PUVA therapy
(151). Elsewhere, topical application of the antifungal ﬂuco-
nazole resulted in free dermal concentrations below the
minimal inhibitory concentration (112). This ability to mea-
sure whether a therapeutic concentration of a drug in the skin
has been attained after topical administration is a particular
advantage of microdialysis. In addition, both the applied drug
and any metabolites formed by biotransformation in the skin
are, in theory, detectable by this method. However, only in a
few exceptional circumstances [e.g., salicylate derivatives
(109)] has signiﬁcant metabolism been observed.
The number of subjects necessary for a microdialysis study
to determine whether two formulations are bioequivalent
depends on the degree of variability observed in the data. From
a practical standpoint, it has been suggested that this problem
should be tackled by ensuring that each subject acts as its own
control (113). Under these circumstances, and performing
duplicate measurements in every volunteer, õ20 subjects are
considered sufﬁcient to distinguish two formulations within the
classic 80–125% conﬁdence interval. In contrast, most micro-
dialysis bioequivalence studies in the literature have been
performed with six to ten volunteers (107,110).
Microdialysis—Unresolved Issues
While many studies comparing microdialysis to other
methods have shown reasonable correlation, further valida-
tion work is essential if this approach is to be recognized by
the regulatory agencies as an option for bioavailability and
bioequivalence assessment. One key issue in the develop-
ment of a standardized protocol is the reproducible insertion
of the microdialysis probe to a consistent depth within the
skin. Probe implantation remains a technical challenge that is
only mastered with patience and practice. Although the
signiﬁcance of probe depth on the resulting permeation
proﬁle is a matter of some debate, it is clear that implantation
in the either the superﬁcial dermis, or the deep dermis or the
subcutaneous tissue can have an obvious impact on the data
obtained (111,112).
A further limitation to the routine application of micro-
dialysis, at the present time, is analysis of the very low levels
of drug in the dialysate. The most successful demonstrations
of the approach have been made with compounds which
readily penetrate the skin and which have decent aqueous
solubilities and low protein binding. Such molecules are rare,
0
20
40
60
80
100
120
140
0 60 120 180 240 300 360
Time (min)
D
e
r
m
a
l
 
c
o
n
c
e
n
t
r
a
t
i
o
n
(
n
g
/
m
l
)
0
50
100
150
200
250
300
350
0 5 10 15 20 25
Time (h)
C
u
m
u
l
a
t
e
d
 
q
u
a
n
t
i
t
y
(
µ
g
/
c
m
2
)
0
50
100
150
200
250
300
350
 gel 1  gel 2
Q
u
a
n
t
i
t
y
 
i
n
 
S
C
 
(
n
g
/
c
m
2
)
Fig. 11. Local availability of ketoprofen applied topically from two gel
formulations: assessment a in vitro in diffusion cells (upper panel), b in
vivo by tape stripping (middle panel), and c by dermal microdialysis
(lower panel; A.-R. Denet and V. Pre ´at, unpublished data).
97 In Vivo Methods for the Assessment of Topical Drug Bioavailabilityhowever, and are not always relevant to dermatological
therapy. Corticosteroids, on the other hand, the vasoconstric-
tion response to which might offer a useful validation Fmarker_
for microdialysis, have never been successfully monitored by
the technique (presumably due to their low permeabilities,
poor aqueous solubilities and high protein binding).
In addition, even though microdialysis may be reason-
ably termed Bminimally invasive,^ its use in vivo is typically
limited to experiments lasting 5–10 h. For slowly permeating
drugs, therefore, the quantities absorbed in this time will be
minimal, and the analytical problems quite daunting.
OTHER APPROACHES
Finally, a few words about some alternative strategies, of
which only confocal Raman spectroscopy is receiving signif-
icant attention at this time.
Skin Biopsy
Skin biopsies, whether to the level of the dermis (shave
biopsy) or through to the sub-cutis (punch biopsy), are
invasive and generally performed under local anaesthesia.
While such methods have a place in dermatological surgery
(to remove warts and small tumours, for example), their
application for tissue sampling and analysis post-drug appli-
cation has not attracted much attention as a routine approach
for use in vivo. Despite the obvious advantage of offering a
Fsnapshot_ of drug disposition in the different skin layers, the
aggressive nature of the biopsy rules out any chance that it
might be adopted as a standard procedure. Even attempts to
minimize tissue trauma (131,152) fail to render the method
remotely acceptable and its use in the foreseeable future will
be restricted to animal and in vitro studies.
Suction Blister
Applying a partial negative pressure to the skin disrupts
the epidermal–dermal junction and forms a blister which ﬁlls
progressively with interstitial ﬂuid and serum (153,154). This
liquid offers a pharmacokinetic Bcompartment,^ therefore, in
which a previously applied drug can be sampled with a
hypodermic needle and quantiﬁed; if multiple blisters are
raised (as is possible with certain commercially available
devices), then a concentration-time proﬁle of the drug in the
skin can be obtained. While on the surface attractive, this
approach is also quite invasive and causes obvious scarring,
albeit over relatively small areas of skin. The technique can
be used to compare topical formulations in a reasonably
objective way (155,156), but the potential binding of the drug
to skin tissue, especially for very lipophilic species, may mean
that very low levels are present, if at all, in the blister ﬂuid
(157). Taken together, this has meant that the procedure has
not been widely used and, once again, is presently viewed as
too invasive for practical and routine application in topical
bioavailability experiments.
Follicle Delivery
Drug delivery to the follicle following application of
formulations to the skin is an established fact. Although the
follicles occupy a relatively small fractional area (on
average, õ0.1%) of the surface, it appears that diffusion
via these appendages is fast relative to that through intact
SC, and probably accounts for the ﬁrst drug molecules
which penetrate deep into the skin (158). Furthermore, the
follicle is a bona ﬁde target for skin diseases, such as acne and
alopecia, and this raises the issue of drug bioavailability to
this speciﬁc structure. For example, it has been claimed that
certain particle sizes are optimal for sequestration in the
follicle (159) thereby concentrating the drug at this site and
subsequently providing a sustained release to the local
environment. However, a method, with which to quantify
such Ftargeting_, has been difﬁcult to validate unequivocally
and no approach can be claimed to have demonstrated
practical utility for quantitative bioavailability/bioequivalence
assessment to the follicle. Nevertheless, there have been some
innovative ideas reported in the literature (77,160,161) and,
more recently, somewhat simpler methodology has been
described, with which the contribution of follicular transport
to the overall permeation of a drug in vivo in man has been
estimated (99,162).
Confocal Raman Spectroscopy
This technique uses the confocal principle to noninva-
sively examine the outer layers of the skin by Raman
spectroscopy. In this way, it is possible to acquire rapidly, in
Table II. Methods to Assess Drug Penetration into and/or Across the Skin
Method Measure Measurement site
Temporal
resolution
Technical
simplicity
In vitro Diffusion cell Q Transport into and
across skin
++ +
In vivo: non- or
minimally invasive
Tape stripping Q Stratum corneum 0 +
ATR-FTIR Q Stratum corneum + +
Raman Q/L Upper skin + +
Microdialysis Q (free) Dermis (or subdermis) ++ j
Vasoconstriction A Microcirculation + T
In vivo: invasive Blister Q Extracellular ﬂuid 0 T
Biopsy Q Skin 0 +
Biopsy Q+L Skin (depth) 0 T
Q Quantity of drug, A pharmacological activity of drug, L drug localization
98 Herkenne et al.vivo in humans, Raman spectra of the skin as a function of
depth (163). The method is able to provide, for example,
information on the hydration of the SC, and the manner in
which the water concentration proﬁle across the barrier may
be altered by the use of moisturizing agents (163–165). Other
analytes, such as urea, can also be examined via their unique
Raman signature which allows them to be differentiated from
the spectrum of the skin_s constituents (166).
The approach is comparable to the application of
reﬂectance infrared spectroscopy described earlier. In distinct
contrast, however, confocal Raman does not require pro-
gressive stripping of the SC to determine the concentration
versus depth proﬁle of a target substance, and this is clearly
an important advantage. Like ATR-IR, however, confocal
Raman requires that the molecule of interest be present at a
sufﬁcient concentration, and possess spectral features of
sufﬁcient intensity, to permit its differentiation from those
of the skin (163). Therein lies, at present, the major drawback
of these IR-based techniques. With confocal Raman, in
addition, only relative concentrations (rather than absolute
levels) can be determined. It remains to be seen, therefore,
whether this signiﬁcant technological development will
contribute eventually to the evaluation of topical drug
bioavailability and/or bioequivalence. For the moment, the
method offers a unique research tool and a novel approach to
evaluate skin moisturization.
CONCLUSIONS
Despite pressure on regulatory agencies, such as the
FDA, there is no generally accepted method with which to
evaluate the bioavailability and bioequivalence of topical
drug products. For the present, therefore, with the exception
of the vasoconstriction assay for corticosteroids, and despite
the diversity of efforts which have been made (Table II),
clinical studies are obligatory. Unlike oral administration, for
example, where the blood level of a drug is a generally
accepted Fsurrogate_ for its concentration at the site of action,
topical drug delivery poses a more complex problem. In this
case, the site of action (even when it is known, which is not
always the case) is not always accessible and a suitable
Fsurrogate_, e.g., the SC, has not been generally validated.
Two approaches are under most intensive scrutiny: one,
microdialysis, strives to make measurements of the drug in a
true Bbiophase^ of the skin; the other, tape-stripping,
attempts to establish the SC as the Fsurrogate_ sampling
site. In both instances, signiﬁcant progress has been made
and proof-of-concept demonstrated. However, the next
steps, i.e., optimization of the procedure(s) and transition
to a useful and practical regulatory test, remain challenges
for future work.
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